Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CTSV | O60911 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892032 | 1.00 | KDM4E (0.66) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL1781100 | 0.93 | KDM4E (0.56) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL2089698 | 0.91 | KDM4E (0.52) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL23459152 | 0.91 | KDM4E (0.52) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL3138320 | 0.89 | CTSV (0.57) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL4728946 | 0.89 | CTSV (0.57) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL4469125 | 0.88 | SMN1; SMN2 (0.52) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL874091 | 0.88 | HTT (0.55) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL340527 | 0.88 | SMN1; SMN2 (0.52) | KDM4ESMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL159448 | 0.88 | HTT (0.55) | KDM4ESMPD1HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| CN-116568689-A | Polycyclic pyrimidine derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022170917-A1 | POLYCYCLIC PYRIMIDINE DERIVATIVE AS SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220162172-A1 | QUINAZOLINONE COMPOUNDS | CEREPEUT, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-3962908-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | Board of Regents, The University of Texas System (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114026083-A | Heterocyclic inhibitors of tyrosine kinases | 德州大学系统董事会 | 2022-02-08 | — | — | CN | disclosed |
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008020302-A2 | HETEROAROMATIC QUINOLINE-BASED COMPOUNDS AS PHOSPHODIESTERASE (PDE) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1384712-B1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BREWERY (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | KDM4E 2073/4885SMPD1 2794/4885HDAC1 4233/4885 |
| US-20220162172-A1 | QUINAZOLINONE COMPOUNDS | NDUFAB1, NDUFV1, NDUFV2 | KDM4E 4109/4885SMPD1 1909/4885HDAC1 951/4885 |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | KDM4E 3631/4885SMPD1 2226/4885HDAC1 3365/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | KDM4E 3579/4885SMPD1 2040/4885HDAC1 3547/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | KDM4E 2073/4885SMPD1 2794/4885HDAC1 4233/4885 |
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | ERBB2, ERBB3, EGFR | KDM4E 2729/4885SMPD1 1718/4885HDAC1 1539/4885 |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | ERBB2, ERBB3, EGFR | KDM4E 2729/4885SMPD1 1718/4885HDAC1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.